Podcast Pearls: Optimizing the Timing and Sequencing of Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer

Download this slideset for key insights from our podcast featuring an expert discussion of the use of key later-line treatment options for patients with mCRC, including optimal treatment sequencing and dosing and how adverse events influence therapy decisions.
person default
Joleen Hubbard, MD
John L. Marshall, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.19 MB
Released: April 29, 2021

Acknowledgements

Supported by an educational grant from
Bayer HealthCare Pharmaceuticals Inc.

Related Content

Latest data on nivolumab plus chemotherapy or ipilimumab for untreated advanced esophageal cancer (CheckMate 648) from ASCO 2021 reported by Clinical Care Options (CCO)

Released: June 11, 2021

Data from ASCO 2021 on the CheckMate 649 trial of first-line nivolumab + chemotherapy for gastroesophageal cancer, as reported by Clinical Care Options (CCO)

Released: June 10, 2021

Get a preview of key studies being presented at ASCO 2021 from experts in solid tumors and hematologic malignancies from Clinical Care Options (CCO)

person default Angeles Alvarez Secord, MD Michael A. Davies, MD, PhD Ian W. Flinn, MD, PhD Shaji K. Kumar, MD Evan J. Lipson, MD Joyce O'Shaughnessy, MD Daniel P. Petrylak, MD Zofia Piotrowska, MD, MHS Elizabeth R. Plimack, MD, MS Karen L. Reckamp, MD, MS Manish A. Shah, MD Eunice S. Wang, MD Released: June 2, 2021

Expert video on new and established therapies targeting HER2/HER3 in gastrointestinal cancers, from Clinical Care Options (CCO)

Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD
Program Director
Daniel Catenacci, MD
Physicians: maximum of 0.5 AMA PRA Category 1 Credits ABIM MOC: maximum of 0.5 Medical Knowledge MOC point(s) Released: May 27, 2021 Expired: May 26, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue